Articles

Polycythemia vera was first recognized by French physician Louis H. Vaquez in 1892 and was known then as maladie de Vaquez. The name poly-cyt-[h]emia originates from the Greek and Latin, and literally means many-cells-in the blood.

Read More ›

This article summarizes 2 analyses from the phase 3 GMMG-HD7 trial presented at ASH 2024, as well as the FDA’s Oncologic Drugs Advisory Committee support for the use of minimal residual disease as an accelerated approval endpoint in multiple myeloma clinical trials. Read More ›

In this article, the results from 2 studies of Isa-KRd in newly diagnosed multiple myeloma (NDMM) are summarized, with the GMMG-CONCEPT trial focusing on high-risk NDMM and the IFM 2020-02 MIDAS study focusing on transplant-eligible NDMM. Read More ›

This article summarizes a post-hoc analysis of data from the MASTER study and the GRIFFIN study of patients with newly diagnosed multiple myeloma with high-risk cytogenetic abnormalities. Read More ›

This article summarizes results from an ad hoc survey conducted to evaluate nurses’ experiences with subcutaneous isatuximab administration via an on-body delivery system. Read More ›

Oncology nurses are often the first to hear about patients’ therapy-induced side effects. Understanding these challenges can help maximize your patients’ quality of life and keep their treatment plan on schedule. Read More ›

“Neither my education in nursing school nor graduate school prepared me for neuro-oncology,” writes Marissa Panzer, DNP, AGPCNP, AOCNP, who shares her experiences navigating the oncology world as a nurse practitioner. Read More ›

As the days grow shorter and darker, it’s easy to fall prey to feelings of sadness and isolation, and although you cannot always avoid experiencing seasonal affective disorder, you can make lifestyle changes to manage it and prevent future episodes. Read More ›

Biomarker testing is crucial in guiding treatment choices by pinpointing individuals who stand to gain from specific regimens, ultimately enhancing patient results. Nevertheless, the application of guideline-endorsed biomarker testing for advanced non–small cell lung cancer patients varies. Read More ›